[go: up one dir, main page]

IN2012DN00733A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00733A
IN2012DN00733A IN733DEN2012A IN2012DN00733A IN 2012DN00733 A IN2012DN00733 A IN 2012DN00733A IN 733DEN2012 A IN733DEN2012 A IN 733DEN2012A IN 2012DN00733 A IN2012DN00733 A IN 2012DN00733A
Authority
IN
India
Prior art keywords
polypeptides
medicaments
well
relates
present
Prior art date
Application number
Other languages
English (en)
Inventor
Fred Hofmann
Jurgen Frevert
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of IN2012DN00733A publication Critical patent/IN2012DN00733A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
IN733DEN2012 2009-07-02 2010-07-01 IN2012DN00733A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27019809P 2009-07-02 2009-07-02
EP09164365 2009-07-02
PCT/EP2010/059398 WO2011000929A1 (fr) 2009-07-02 2010-07-01 Neurotoxines présentant une activité biologique raccourcie

Publications (1)

Publication Number Publication Date
IN2012DN00733A true IN2012DN00733A (fr) 2015-06-19

Family

ID=40911088

Family Applications (1)

Application Number Title Priority Date Filing Date
IN733DEN2012 IN2012DN00733A (fr) 2009-07-02 2010-07-01

Country Status (14)

Country Link
US (4) US8586329B2 (fr)
EP (1) EP2449101B1 (fr)
JP (2) JP6059986B2 (fr)
KR (2) KR101818895B1 (fr)
CN (1) CN102471765B9 (fr)
AU (1) AU2010267963B2 (fr)
BR (1) BRPI1014253A2 (fr)
CA (1) CA2763692A1 (fr)
ES (1) ES2693705T3 (fr)
IL (1) IL216414A (fr)
IN (1) IN2012DN00733A (fr)
MX (2) MX2011013014A (fr)
RU (1) RU2582266C2 (fr)
WO (1) WO2011000929A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US9746475B2 (en) 2011-03-14 2017-08-29 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
TWI583792B (zh) * 2011-11-09 2017-05-21 曼茲法瑪股份有限公司 展現減短的生物活性之神經毒素
AU2013304767A1 (en) 2012-08-20 2015-02-26 Merz Pharma Gmbh & Co. Kgaa Novel method for the manufacturing of recombinant proteins harbouring an N-terminal lysine
EP2909207A1 (fr) 2012-10-16 2015-08-26 Almirall S.A. Dérivés de pyrrolotriazinone en tant qu'inhibiteurs des pi3k
US10087432B2 (en) 2012-11-21 2018-10-02 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
EA034575B1 (ru) 2013-04-18 2020-02-21 Фондацьоне Телетон Эффективная доставка больших генов посредством двойных aav векторов
ES2642916T3 (es) 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
US20170112907A1 (en) 2014-06-13 2017-04-27 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
WO2015188943A1 (fr) 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Utilisation de neurotoxines clostridiales recombinées pour le traitement de patients souffrant de certains troubles associés aux muscles
US20170119863A1 (en) * 2014-06-13 2017-05-04 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
US20170128551A1 (en) * 2014-06-13 2017-05-11 Klaus Fink Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
WO2016102068A1 (fr) 2014-12-23 2016-06-30 Merz Pharma Gmbh & Co. Kgaa Récipient pré-rempli de toxine botulinique
US10647750B2 (en) 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins
US20180327779A1 (en) * 2015-03-03 2018-11-15 Fondazione Telethon (IT/IT) Multiple vector system and uses thereof
WO2016168740A2 (fr) * 2015-04-16 2016-10-20 Spencer Juliet V Détection de cytomégalovirus humain dans le cancer du sein
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
KR101793328B1 (ko) * 2015-07-03 2017-11-03 씨제이제일제당 (주) Ｌ-라이신 생산능을 갖는 미생물 및 이를 이용한 ｌ-라이신 생산 방법
WO2017063743A1 (fr) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Améliorations apportées à la thérapie par ultrasons de tissu atteint de photovieillissement
EP3423084B1 (fr) 2016-03-02 2021-09-01 Merz Pharma GmbH & Co. KGaA Composition comprenant de la toxine botulique
WO2017209287A1 (fr) * 2016-06-02 2017-12-07 学校法人藤田学園 Antigène d'allergie aux œufs
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3290437A1 (fr) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Nouvelles neurotoxines clostridiales recombinantes avec augmentation de la durée d'effet
EP3312193A1 (fr) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Nouvelles neurotoxines botuliques recombinantes à augmentation de la durée d'effet
TWI871271B (zh) * 2016-11-28 2025-02-01 德商Ｃ 樂克塔股份有限公司 海藻糖磷酸化酶
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
ES2930237T3 (es) 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
WO2019158745A1 (fr) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Neurotoxine botulique reposant sur un acide nucléique, pour application thérapeutique
WO2019178116A1 (fr) 2018-03-12 2019-09-19 Conagen Inc. Production biosynthétique du glycoside de stéviol rébaudioside j et rébaudioside n
CN112135840B (zh) * 2018-03-13 2024-01-23 斯米维特公司 与破伤风神经毒素结合的单域抗体
US10751399B2 (en) * 2018-03-20 2020-08-25 Cho Pharma Usa, Inc. Chimeric antigen receptors that bind to SSEA4 and uses thereof
CN118956813A (zh) * 2018-05-02 2024-11-15 天野酶制品株式会社 修饰型酯酶和其用途
CN108588087B (zh) * 2018-05-16 2022-06-03 南京农业大学 一种提高植物抗病性的基因GmLecRK-R及其应用
WO2020131252A1 (fr) * 2018-12-21 2020-06-25 Fornia Biosolutions, Inc. Compositions de glucoamylase g6p g7p variant et procédés
CN109998055B (zh) * 2019-04-09 2022-03-25 黑龙江省科学院大庆分院 一种汉麻籽抗氧化多肽咀嚼片及其制备方法
CN110100945B (zh) * 2019-05-05 2022-05-03 黑龙江省科学院大庆分院 一种汉麻降血脂肽组合物及其应用
WO2020253537A1 (fr) * 2019-06-21 2020-12-24 苏州克睿基因生物科技有限公司 Procédé et kit de détection du virus de la peste porcine africaine
CN110295150A (zh) * 2019-07-17 2019-10-01 天津润德生物科技有限公司 一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
CN110540996B (zh) * 2019-08-29 2022-01-28 华中农业大学 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用
SI4037708T1 (sl) 2019-09-30 2025-01-31 Gilead Sciences, Inc. Cepiva proti hbv in postopki zdravljenja hbv
CN110643616A (zh) * 2019-10-22 2020-01-03 云南省烟草农业科学研究院 一种烟草降烟碱合成调控基因NtERF91的克隆和应用
CN115151556A (zh) * 2020-02-22 2022-10-04 Jcr制药股份有限公司 人转铁蛋白受体结合肽
CN112540178B (zh) * 2020-08-06 2023-12-19 武汉天德生物科技有限公司 一种检测早期老年痴呆症的免疫组化试剂盒及其使用方法
CN112662644B (zh) * 2021-01-19 2022-04-22 华南理工大学 一种甘油磷酸二酯磷酸二酯酶突变体及其应用
CN113899907B (zh) * 2021-09-07 2023-06-27 中国农业科学院油料作物研究所 一步式高效筛选黄曲霉毒素绿色防控材料的方法及其应用
CN115109759B (zh) * 2022-06-24 2024-05-03 浙江工业大学 羰基还原酶LsCR突变体、工程菌及在不对称还原羰基化合物制备手性醇中的应用
CN115944721B (zh) * 2022-12-14 2025-11-25 内蒙古华希生物科技有限公司 一种免疫组合物、其制备方法及应用
CN117741160B (zh) * 2023-12-21 2024-07-12 汉王科技股份有限公司 嗅觉受体在识别乙醇中的用途和检测乙醇的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20060004334A1 (en) 2004-06-30 2006-01-05 Kimberly-Clark Worldwide, Inc. Stabilized absorbent structures
US7825233B2 (en) * 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
CN101005853B (zh) 2004-07-26 2011-05-04 莫茨药物股份两合公司 包含肉毒杆菌神经毒素的治疗组合物

Also Published As

Publication number Publication date
US20160030511A1 (en) 2016-02-04
US9827298B2 (en) 2017-11-28
US20120107362A1 (en) 2012-05-03
CN102471765B9 (zh) 2016-07-27
MX2011013014A (es) 2012-01-27
BRPI1014253A2 (pt) 2016-04-12
US20170072030A1 (en) 2017-03-16
US9193771B2 (en) 2015-11-24
US8586329B2 (en) 2013-11-19
RU2012103376A (ru) 2013-08-10
CN102471765A (zh) 2012-05-23
JP2015231378A (ja) 2015-12-24
US20140045760A1 (en) 2014-02-13
AU2010267963A1 (en) 2011-12-22
MX352265B (es) 2017-11-16
ES2693705T3 (es) 2018-12-13
WO2011000929A1 (fr) 2011-01-06
EP2449101A1 (fr) 2012-05-09
CN102471765B (zh) 2016-05-11
AU2010267963B2 (en) 2015-09-24
RU2582266C2 (ru) 2016-04-20
HK1171246A1 (zh) 2013-03-22
JP2012531191A (ja) 2012-12-10
CA2763692A1 (fr) 2011-01-06
US9511114B2 (en) 2016-12-06
IL216414A0 (en) 2012-02-29
EP2449101B1 (fr) 2018-10-10
KR20170016529A (ko) 2017-02-13
IL216414A (en) 2016-08-31
KR20120104140A (ko) 2012-09-20
KR101818895B1 (ko) 2018-01-15
JP6059986B2 (ja) 2017-01-11

Similar Documents

Publication Publication Date Title
IN2012DN00733A (fr)
MX2014005544A (es) Neurotoxinas que exhiben actividad biologica acortada.
WO2012069655A3 (fr) Modules de coiffage n-terminal améliorés pour des protéines de répétitions d'ankyrine conçues
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MY161268A (en) PEPTIDE OR PEPTIDE COMPLEX BINDING TO α2 INTEGRIN AND METHODS AND USES INVOLVING THE SAME
MX374682B (es) Moléculas de unión a 4-1bb.
MX2014009909A (es) Acido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilacion para incrementar la expresion de un antigeno tumoral codificado.
MX2011013457A (es) Polipeptidos que enlazan quimioquina novedosos capaces de inhibir el curso de autoinmunidad, inflamacion y cancer.
ATE548381T1 (de) Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus
WO2010099477A3 (fr) Motifs structuraux de polypeptides associés à une activité de signalisation cellulaire
EA201171148A1 (ru) Антитело-антагонист, специфичное для гетеродимера альфа-4-бета-7
MX2011013903A (es) Polipeptidos quimericos y usos de los mismos.
TN2012000167A1 (en) Human il-23 antigen binding proteins
WO2013040093A3 (fr) Compositions de peptide-2 de type glucagon et leurs procédés de fabrication et d'utilisation
IL202443B (en) Nucleic acid encoding it and a pharmaceutical preparation containing the protein, a fusion protein for nucleic acid
WO2011123683A3 (fr) Cytokines activées par des protéases
MX351502B (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
ATE512980T1 (de) Polypeptide mit beta-glucosidase-aktivität sowie diese codierende polynukleotide
WO2010099219A3 (fr) Ligands de conception de la superfamille de tgf-bêta
EA201590195A1 (ru) Днк-кодированные библиотеки, содержащие связи кодирующих олигонуклеотидов, не доступные для считывания полимеразами
WO2009149339A3 (fr) Peptides activateurs de p53
EP4276180A3 (fr) Enzyme de clostridium histolyticum
WO2011002977A3 (fr) Photomanipulation génétiquement codée des protéines et de l'activité peptidique
PH12016500275B1 (en) Antibodies
WO2013052946A3 (fr) Biocapteurs génétiquement codés